Brown C G, Jenkins J, Werman H A, Van Ligten P, Ashton J, Hamlin R L
Department of Preventive Medicine, Ohio State University, Columbus 43210.
Resuscitation. 1989 Jun;17(3):243-50. doi: 10.1016/0300-9572(89)90040-3.
Several recent studies have suggested that adrenergic drugs with peripheral postsynaptic alpha-2 agonist properties increase aortic diastolic pressure (ADP), and thus in the setting of CPR, may improve myocardial blood flow (MBF). This preliminary study investigated the effect of UK14,304-18, a postsynaptic alpha-2 adrenergic agonist on ADP, MBF, myocardial oxygen delivery/utilization (MDO2/MVO2), endocardial/epicardial blood flow ratio (EN/EP), coronary sinus oxygen content (CcsO2) and extraction ratio (ER) during CPR. Five swine were instrumented for MBF measurements using tracer microspheres. Catheters were also placed to measure arterial oxygen content (CaO2) and CcsO2. ADP, MBF, MDO2/MVO2, EN/EP, ER, CaO2 and CcsO2 were measured during normal sinus rhythm (NSR), and during CPR following a 10-min cardiorespiratory arrest. Following this, each animal received 2.0 mg/kg of UK14,304-18 through a right atrial line. ADP, MBF, MDO2/MVO2, EN/EP, ER, CaO2 and CcsO2 were again determined. Defibrillation was then attempted. To determine whether UK14,304-18 improved ADP, MBF and MDO2 over MVO2, compared to CPR alone, results were compared using a paired Student t-test. Statistical significance was considered at the P less than or equal to 0.05 level. No significant improvement in ADP, MBF, MDO2 or ER was noted following the administration of UK14,304-18. The lack of improvement in ADP and MBF may be secondary to a centrally acting postsynaptic alpha-2 agonist effect because of disruption of the blood brain barrier following a prolonged cardiac arrest or because of pharmacologically or structurally distinct populations of peripheral postsynaptic alpha-2 adrenoreceptors that develop in this setting.(ABSTRACT TRUNCATED AT 250 WORDS)
最近的几项研究表明,具有外周突触后α-2激动剂特性的肾上腺素能药物可提高主动脉舒张压(ADP),因此在心肺复苏(CPR)过程中,可能会改善心肌血流量(MBF)。这项初步研究调查了突触后α-2肾上腺素能激动剂UK14,304-18在CPR期间对ADP、MBF、心肌氧输送/利用(MDO2/MVO2)、心内膜/心外膜血流比(EN/EP)、冠状窦氧含量(CcsO2)和提取率(ER)的影响。五只猪通过示踪微球进行MBF测量。还放置了导管来测量动脉氧含量(CaO2)和CcsO2。在正常窦性心律(NSR)期间以及10分钟心肺骤停后的CPR期间,测量ADP、MBF、MDO2/MVO2、EN/EP、ER、CaO2和CcsO2。在此之后,每只动物通过右心房导管接受2.0mg/kg的UK14,304-18。再次测定ADP、MBF、MDO2/MVO2、EN/EP、ER、CaO2和CcsO2。然后尝试除颤。为了确定与单独的CPR相比,UK14,304-18是否能改善ADP、MBF和MDO2相对于MVO2的情况,使用配对学生t检验比较结果。P小于或等于0.05水平被认为具有统计学意义。给予UK14,304-18后,未观察到ADP、MBF、MDO2或ER有显著改善。ADP和MBF缺乏改善可能继发于中枢作用的突触后α-2激动剂效应,这是由于长时间心脏骤停后血脑屏障的破坏,或者是由于在这种情况下出现的药理学或结构上不同的外周突触后α-2肾上腺素能受体群体。(摘要截断于250字)